AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
phenelzine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 2123 | 51-71-8 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
One of the MONOAMINE OXIDASE INHIBITORS used to treat DEPRESSION; PHOBIC DISORDERS; and PANIC.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 60 | mg | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| S (Water solubility) | 50 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AKT1,AKT2,AKT3,ALK,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,CHEK1,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK1,JAK2,JAK3,MAP2K6,MAP3K21,MAP3K7,MAP4K3,MAPK12,MAPK7,MAPK9,MAPKAPK2,MARK4,MET,MTOR,NTRK2,PAK4,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1 | 54 | |||
| kinase-selectivity-class | AKT2,AKT3,AXL,BRAF,CAMK2D,CDK7,DDR1,EIF2AK3,EPHB4,FLT3,GRK2,INSR,MAP4K1,MAP4K3,MAPK12,MAPK7,MELK,NUAK1,PAK4,PDK4,PRKACA,PRKCD,PRKG1,ROCK1,SIK2,SIK3,STK33,TEK,ULK2 | 29 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| June 9, 1961 | FDA | PARKE DAVIS |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Serotonin syndrome | 130.24 | 35.76 | 38 | 1080 | 37849 | 90589480 |
| Drug interaction | 94.16 | 35.76 | 52 | 1066 | 276401 | 90350928 |
| Product complaint | 48.30 | 35.76 | 14 | 1104 | 13486 | 90613843 |
| Hypertensive crisis | 44.49 | 35.76 | 14 | 1104 | 17770 | 90609559 |
| Food interaction | 35.79 | 35.76 | 7 | 1111 | 1257 | 90626072 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drug ineffective | 43.24 | 41.53 | 42 | 411 | 630155 | 41990727 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Serotonin syndrome | 141.86 | 31.87 | 44 | 1200 | 59109 | 110528946 |
| Drug interaction | 98.63 | 31.87 | 64 | 1180 | 500119 | 110087936 |
| Hypertensive crisis | 33.68 | 31.87 | 12 | 1232 | 24360 | 110563695 |
| Food interaction | 32.71 | 31.87 | 7 | 1237 | 2145 | 110585910 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N06AF03 | NERVOUS SYSTEM PSYCHOANALEPTICS ANTIDEPRESSANTS Monoamine oxidase inhibitors, non-selective |
| FDA MoA | N0000000184 | Monoamine Oxidase Inhibitors |
| MeSH PA | D000928 | Antidepressive Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D008996 | Monoamine Oxidase Inhibitors |
| MeSH PA | D011619 | Psychotropic Drugs |
| FDA EPC | N0000175744 | Monoamine Oxidase Inhibitor |
| CHEBI has role | CHEBI:35469 | antidepressant |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
Related Drugs by ATC class:
N06AF Monoamine oxidase inhibitors, non-selective 5 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Depressive disorder | indication | 35489007 | |
| Bulimia nervosa | off-label use | 78004001 | |
| Suicidal thoughts | contraindication | 6471006 | |
| Alcoholism | contraindication | 7200002 | |
| Bipolar disorder | contraindication | 13746004 | DOID:3312 |
| Feeling agitated | contraindication | 24199005 | |
| Orthostatic hypotension | contraindication | 28651003 | |
| Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Conduction disorder of the heart | contraindication | 44808001 | |
| Low blood pressure | contraindication | 45007003 | |
| Chronic heart failure | contraindication | 48447003 | |
| Anxiety | contraindication | 48694002 | |
| Disorder of cardiovascular system | contraindication | 49601007 | DOID:1287 |
| Schizophrenia | contraindication | 58214004 | DOID:5419 |
| Cerebrovascular disease | contraindication | 62914000 | DOID:6713 |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Seizure disorder | contraindication | 128613002 | |
| Liver function tests abnormal | contraindication | 166603001 | |
| Angina pectoris | contraindication | 194828000 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Hypoglycemic disorder | contraindication | 237630007 | |
| Syncope | contraindication | 271594007 | |
| Pheochromocytoma | contraindication | 302835009 | |
| Myelogram | contraindication | 367401004 | |
| Disorder of coronary artery | contraindication | 414024009 | |
| Hypertensive Emergencies | contraindication | ||
| Severe Headache Disorder | contraindication | ||
| Frequent Headache Disorder | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 7.59 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Amine oxidase [flavin-containing] A | Enzyme | INHIBITOR | IC50 | 6.84 | DRUG MATRIX | CHEMBL | |||
| Amine oxidase [flavin-containing] B | Enzyme | INHIBITOR | Ki | 7.82 | IUPHAR | CHEMBL | |||
| Cytochrome P450 2D6 | Enzyme | IC50 | 6 | DRUG MATRIX | |||||
| Cytochrome P450 2C8 | Enzyme | INHIBITOR | Ki | 5.14 | IUPHAR | ||||
| Cytochrome P450 2C9 | Enzyme | IC50 | 5.40 | DRUG MATRIX | |||||
| Cytochrome P450 2C19 | Enzyme | IC50 | 6.10 | DRUG MATRIX | |||||
| Membrane primary amine oxidase | Enzyme | IC50 | 7.70 | CHEMBL | |||||
| Indoleamine 2,3-dioxygenase 1 | Enzyme | IC50 | 4.85 | CHEMBL | |||||
| Lysine-specific histone demethylase 1A | Enzyme | Ki | 4.75 | CHEMBL | |||||
| Cytochrome P450 3A4 | Enzyme | IC50 | 5.70 | DRUG MATRIX | |||||
| FAD-linked sulfhydryl oxidase ALR | Enzyme | AC50 | 5.12 | CHEMBL | |||||
| Sodium-dependent dopamine transporter | Transporter | Ki | 5.08 | PDSP | |||||
| Amine oxidase [flavin-containing] B | Enzyme | IC50 | 7.12 | CHEMBL | |||||
| Amine oxidase [flavin-containing] A | Enzyme | IC50 | 7.52 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019886 | VUID |
| N0000147971 | NUI |
| D00505 | KEGG_DRUG |
| 156-51-4 | SECONDARY_CAS_RN |
| 4018632 | VANDF |
| 4019886 | VANDF |
| C0031392 | UMLSCUI |
| CHEBI:8060 | CHEBI |
| CHEMBL1089 | ChEMBL_ID |
| 3675 | PUBCHEM_CID |
| DB00780 | DRUGBANK_ID |
| CHEMBL1200895 | ChEMBL_ID |
| D010624 | MESH_DESCRIPTOR_UI |
| 919 | INN_ID |
| 7266 | IUPHAR_LIGAND_ID |
| O408N561GF | UNII |
| 8123 | RXNORM |
| 178818 | MMSL |
| 5269 | MMSL |
| d00883 | MMSL |
| 001495 | NDDF |
| 004596 | NDDF |
| 21614004 | SNOMEDCT_US |
| 387528000 | SNOMEDCT_US |
| 9500005 | SNOMEDCT_US |
| O408N561GF | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Nardil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0071-0350 | TABLET, FILM COATED | 15 mg | ORAL | NDA | 19 sections |
| Phenelzine Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 40032-360 | TABLET | 15 mg | ORAL | ANDA | 13 sections |
| Phenelzine Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43386-360 | TABLET | 15 mg | ORAL | ANDA | 15 sections |
| phenelzine sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 59762-0119 | TABLET, FILM COATED | 15 mg | ORAL | NDA AUTHORIZED GENERIC | 20 sections |